Acute promyelocytic leukemia Primary Prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute promyelocytic leukemia}}
{{Acute promyelocytic leukemia}}
{{CMG}}; {{AE}} {{S.G.}}
{{CMG}}; {{AE}} {{S.G.}}; {{GRR}} {{Nat}}


==Overview==
==Overview==
There are no established measures for the primary prevention of acute promyelocytic leukemia  
* There are no established measures for the primary prevention of acute promyelocytic leukemia.
 
* There are no available vaccines against acute promyelocytic leukemia.
There are no available vaccines against acute promyelocytic leukemia .
 
Effective measures for the primary prevention of acute promyelocytic leukemia in fatal is


==Primary Prevention==
==Primary Prevention==
Line 14: Line 11:
* There are no available vaccines against acute promyelocytic leukemia .
* There are no available vaccines against acute promyelocytic leukemia .


* Effective measures for the primary prevention of acute promyelocytic leukemia include:<ref name="pmid250566972">{{cite journal |vauthors=Grove CS, Vassiliou GS |title=Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? |journal=Dis Model Mech |volume=7 |issue=8 |pages=941–51 |date=August 2014 |pmid=25056697 |doi=10.1242/dmm.015974 |url=}}</ref><ref name="pmid221664972">{{cite journal |vauthors=McHale CM, Zhang L, Smith MT |title=Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment |journal=Carcinogenesis |volume=33 |issue=2 |pages=240–52 |date=February 2012 |pmid=22166497 |pmc=3271273 |doi=10.1093/carcin/bgr297 |url=}}</ref>
* Effective measures for the primary prevention of acute promyelocytic leukemia include:<ref name="pmid250566972">{{cite journal |vauthors=Grove CS, Vassiliou GS |title=Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? |journal=Dis Model Mech |volume=7 |issue=8 |pages=941–51 |date=August 2014 |pmid=25056697 |doi=10.1242/dmm.015974 |url=}}</ref><ref name="pmid221664972">{{cite journal |vauthors=McHale CM, Zhang L, Smith MT |title=Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment |journal=Carcinogenesis |volume=33 |issue=2 |pages=240–52 |date=February 2012 |pmid=22166497 |pmc=3271273 |doi=10.1093/carcin/bgr297 |url=}}</ref><ref name="pmid27913456">{{cite journal |vauthors=Abedin S, Altman JK |title=Acute promyelocytic leukemia: preventing early complications and late toxicities |journal=Hematology Am Soc Hematol Educ Program |volume=2016 |issue=1 |pages=10–15 |date=December 2016 |pmid=27913456 |pmc=6142484 |doi=10.1182/asheducation-2016.1.10 |url=}}</ref><ref name="CasorelliBossa2012">{{cite journal|last1=Casorelli|first1=Ida|last2=Bossa|first2=Cecilia|last3=Bignami|first3=Margherita|title=DNA Damage and Repair in Human Cancer: Molecular Mechanisms and Contribution to Therapy-Related Leukemias|journal=International Journal of Environmental Research and Public Health|volume=9|issue=8|year=2012|pages=2636–2657|issn=1660-4601|doi=10.3390/ijerph9082636}}</ref><ref name="GreimKaden2014">{{cite journal|last1=Greim|first1=Helmut|last2=Kaden|first2=Debra A.|last3=Larson|first3=Richard A.|last4=Palermo|first4=Christine M.|last5=Rice|first5=Jerry M.|last6=Ross|first6=David|last7=Snyder|first7=Robert|title=The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment|journal=Annals of the New York Academy of Sciences|volume=1310|issue=1|year=2014|pages=7–31|issn=00778923|doi=10.1111/nyas.12362}}</ref>


**White blood cell (WBC) count more than 10,000,000,000
**[[White blood cells|White blood cell]] (WBC) count more than 10,000,000,000
**Advanced age (Age> 60)
**Advanced [[age]] (Age> 60)
**Prevent  to exposure benzene
**Prevent  to exposure [[benzene]] and [[radiation]]


==References==
==References==

Latest revision as of 13:13, 11 April 2019

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia Primary Prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia Primary Prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia Primary Prevention

CDC on Acute promyelocytic leukemia Primary Prevention

Acute promyelocytic leukemia Primary Prevention in the news

Blogs on Acute promyelocytic leukemia Primary Prevention

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia Primary Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

  • There are no established measures for the primary prevention of acute promyelocytic leukemia.
  • There are no available vaccines against acute promyelocytic leukemia.

Primary Prevention

  • There are no established measures for the primary prevention of acute promyelocytic leukemia .
  • There are no available vaccines against acute promyelocytic leukemia .
  • Effective measures for the primary prevention of acute promyelocytic leukemia include:[1][2][3][4][5]

References

  1. Grove CS, Vassiliou GS (August 2014). "Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?". Dis Model Mech. 7 (8): 941–51. doi:10.1242/dmm.015974. PMID 25056697.
  2. McHale CM, Zhang L, Smith MT (February 2012). "Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment". Carcinogenesis. 33 (2): 240–52. doi:10.1093/carcin/bgr297. PMC 3271273. PMID 22166497.
  3. Abedin S, Altman JK (December 2016). "Acute promyelocytic leukemia: preventing early complications and late toxicities". Hematology Am Soc Hematol Educ Program. 2016 (1): 10–15. doi:10.1182/asheducation-2016.1.10. PMC 6142484. PMID 27913456.
  4. Casorelli, Ida; Bossa, Cecilia; Bignami, Margherita (2012). "DNA Damage and Repair in Human Cancer: Molecular Mechanisms and Contribution to Therapy-Related Leukemias". International Journal of Environmental Research and Public Health. 9 (8): 2636–2657. doi:10.3390/ijerph9082636. ISSN 1660-4601.
  5. Greim, Helmut; Kaden, Debra A.; Larson, Richard A.; Palermo, Christine M.; Rice, Jerry M.; Ross, David; Snyder, Robert (2014). "The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment". Annals of the New York Academy of Sciences. 1310 (1): 7–31. doi:10.1111/nyas.12362. ISSN 0077-8923.

Template:WH Template:WS